The LOTIS clinical trial program
[402-311] – A Phase 3 Randomized Study of Loncastuximab Tesirine-lpyl Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT04384484
Status: Active, not recruiting
A Phase 1b, Open-label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine-lpyl in Combination With Other Anticancer Agents in Patients with Relapsed or Refractory B-cell Lineage Non-Hodgkin Lymphoma (B-NHL)
NCT04970901
Status: Recruiting
[402-201] – A Phase 2 Open-label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine-lpyl in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT03589469
Status: Completed
![Image for: [402-101] – A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non-Hodgkin Lymphoma (B-NHL)](https://www.adctherapeutics.com/wp-content/uploads/2025/02/logo_lotis-1.jpg){kind=logo}
[402-101] – A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non-Hodgkin Lymphoma (B-NHL)
NCT02669017
Status: Completed